Budd-Chiari syndrome and anticoagulation therapy

doi:10.3877/cma.j.issn.1674-0793.2018.05.019

Abstract

Abstract:

Budd-Chiari syndrome (B-CS) is a kind of post-hepatic portal hypertension, which is threatening human health and occurs differently in epidemiology. With the development of basic and clinical research of B-CS, its etiology, pathophysiology and clinical therapeutics have been achieved great progress. Because of the differences of geography and etiology, the coagulation and anticoagulation therapy on B-CS are controversial both at home and abroad all the time. In this paper, the current status of anticoagulation therapy on B-CS in recent years is reviewed.

Key words: Budd-Chiari syndrome, Anticoagulation, Complication, Hepatic fibrosis

Suxin Li, Luhao Li, Xiaowei Dang. Budd-Chiari syndrome and anticoagulation therapy[J]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(05): 363-366.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2018.05.019

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2018/V12/I05/363

References 34

[1]	Zhang XM, Li QL. Etiology, treatment, and classification of Budd-Chiari syndrome[J]. Chin Med J (Engl), 2007,120(2):159-161.
[2]	Seijo S, Garcia Pagan JC. An overview of current treatment methods for Budd-Chiari syndrome[J]. Exp Opin Orphan Drugs, 2014,2(2):147-157.
[3]	Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management[J]. Hepatology, 2013,57(5):1962-1968.
[4]	Darwish MS, Plessier A, Hernandez Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome[J]. Ann Intern Med, 2009,151(3):167-175.
[5]	Qi X, Wu F, Ren W, et al. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature[J]. Thromb Haemost, 2013,109(5):878-884.
[6]	党晓卫. 布-加综合征下腔静脉病变隔膜形态学和相关基因筛选研究[D]. 郑州：郑州大学, 2010.
[7]	Bittencourt PL, Couto CA, Ribeiro DD. Portal vein thrombosis and Budd-Chiari Syndrome[J]. Clin Liver Dis,13(1):127-144.
[8]	Plompen EP, Schouten JN, Janssen HL. Role of anticoagulant therapy in liver disease[J]. Hepatol Int, 2013,7(2):369-376.
[9]	Akyüz F, Cakaloğlu Y, Pinarbaşi B, et al. Anticoagulant therapy and Budd-Chiari syndrome: is it successful? [J] . Hepatogastroenterology, 2011,58(107-108):900-903.
[10]	Raza SM, Zainab S, Shamsaeefar AR, et al. Experience of liver transplant in patients diagnosed with Budd-Chiari syndrome[J]. Exp Clin Transplant, 2017:1-2.
[11]	Mitsuoka H, Saito T, Higashi S. Stepwise angioplasty and catheter directed thrombolysis for Budd-Chiari syndrome complicated with floating thrombus in inferior vena cava[J]. Ann Vasc Dis, 2014,7(2):173-177.
[12]	Xu H, Zu MH. Interventional therapy of Budd-Chiari syndrome complicated with thrombosis[J]. Chin J Radiol, 2001,35(1):24-27.
[13]	Darwish MS, Valla DC, De Groen PC, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis[J]. Am J Gastroenterol, 2006,101(1):83-90.
[14]	Sakr MA, Abdelkader N, Dabbous H, et al. Prevalence of portal vein thrombosis in Egyptian patients with Budd-Chiari syndrome[J]. Indian J Gastroenterol, 2014,33(5):489-491.
[15]	Sarin SK, Sollano JD, Chawla YK, et al. Consensus on extra-hepatic portal vein obstruction[J]. Liver Int, 2006,26(5):512-519.
[16]	Plessier A, Murad SD, Hernandez GM, et al. A prospective multicentric follow-up study on 105 patients with acute portal vein thrombosis(PVT): results from the European network for vascular disorders of the liver (EM-VIE)[J]. Hepatology, 2007,46:309.
[17]	MacNicholas R, Olliff S, Elias E, et al. An update on the diagnosis and management of Budd-Chiari syndrome[J]. Expert Rev Gastroenterol Hapatol, 2012,6(6):731-744.
[18]	Shukla A, Bhatia SJ. Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone[J]. Indian J Gastroenterol, 2010,29(1):8-11.
[19]	Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing[J]. Br J Haematol, 2009,147(1):77-82.
[20]	Brodsky A, Mazzocchi O, Sánchez F, et al. Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation[J]. Exp Hematol Oncol, 2012,1(1):26.
[21]	Hatab H, Mohammed F, Stockwell R, et al. Membranous Budd-Chiari syndrome in a well-anticoagulated patient[J]. BMJ Case Rep, 2010, 2010.
[22]	Ke Z, Hao X, Ning W, et al. Fibrinolysis status in the Budd-Chiari syndrome in China[J]. Blood Coagul Fibrinolysis, 2015,26(7):721-726.
[23]	Mancuso A. An update on management of Budd-Chiari syndrome[J]. Ann Hepatol, 2014,13(3):323-326.
[24]	党晓卫，李鹏，乔师师, 等. 布加综合征和肝内型门静脉高压症肝脏病理学改变的对比研究[J]. 中华普通外科杂志, 2012,27(5):384-387.
[25]	Burroughs AK. Management of portalhy pertension, Budd-Chiari syndrome and portal vein thrombosis[J]. Medicine, 2011,39(10):607-611.
[26]	Dabbous H, Sakr M, Abdelhakam S, et al. Feasibility of anticoagulation in patients of Budd-Chiari syndrome with gastroesophageal varices and portal hypertension[J]. J GHR, 2013,2(5):581-584.
[27]	Rautou PE, Douarin L, Denninger MH, et al. Bleeding in patients with Budd-Chiari syndrome[J]. J Hepatol, 2011,54(1):56-63.
[28]	Devarbhavi H, Murali AR. Safety of ascitic paracentesis in patients with Budd-Chiari syndrome on oral anticoagulation and elevated international normalized ratio[J]. J Clin Exp Hepatol, 2015,5(4):310-313.
[29]	Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome[J]. Hepatology, 2006,44(5):1308-1316.
[30]	Darwish MS, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome[J]. Hepatology, 2004,39(2):500-508.
[31]	Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: Possible role in the development of parenchymal extinction and portal hypertension[J]. Hepatology, 1995,21(5):1238-1247.
[32]	Mancuso A. The ischemic liver cirrhosis theory and its clinical implications[J]. Med Hypotheses, 2016,94:4-6.
[33]	Assy N, Hussein O, Khalil A, et al. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis[J]. Dig Dis Sci, 2007,52(5):1187-1193.
[34]	Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J]. Gastroenterology, 2012,143(5):1253-1260.

Please choose a citation manager

Content to export